Adrenal insufficiency and diabetes intersect through cortisol, the adrenal hormone that raises blood glucose by driving gluconeogenesis and blocking insulin action at the muscle. When the adrenal cortex fails, cortisol falls and insulin sensitivity rises sharply. In a person with diabetes, this produces unexplained hypoglycemia, sometimes months before fatigue, weight loss, and salt craving appear. The clinical hazard runs both directions: undiagnosed adrenal insufficiency can make routine insulin dosing dangerous, and autoimmune adrenal failure clusters with type 1 diabetes in up to 12 percent of cases in some cohorts. Diagnosis rests on a morning cortisol and ACTH stimulation test, not on symptoms alone.
The Cortisol-Insulin Counter-Regulatory Loop
Blood glucose is a balance between insulin lowering it and a set of counter-regulatory hormones raising it. Cortisol is the slow, steady arm of that counterweight. It enters the liver and increases the enzymes for gluconeogenesis, converting amino acids and glycerol into new glucose. It also reduces glucose uptake in skeletal muscle and adipose tissue.
The mechanism matters for diabetes because cortisol and insulin act on overlapping pathways in opposite directions. Cortisol upregulates phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, the rate-limiting enzymes of hepatic glucose output. Insulin suppresses both. Remove cortisol and the liver's basal glucose release falls, sometimes by 20 to 30 percent in the fasting state. In plain terms: no cortisol means the liver stops topping up blood sugar between meals.
Adrenal insufficiency removes that top-up. The result is not just low cortisol but a shift in the whole counter-regulatory set. Growth hormone and glucagon can partially compensate, but they cannot fully replace cortisol's permissive effect on glucagon action. This is why hypoglycemia in adrenal insufficiency can be profound and resistant to a single glucose dose.
The loop also explains a non-obvious detail: the adrenal medulla sits inside the cortex and depends on cortisol delivered by intra-adrenal portal flow to make epinephrine. In primary adrenal insufficiency, loss of that cortisol supply blunts epinephrine output. The patient loses two defense lines against hypoglycemia at once, cortisol and epinephrine, which is why fasting hypoglycemia appears earlier and is more severe than the cortisol deficit alone would predict.
Quantified Context: How Often They Coexist
The overlap is not rare, and the numbers differ sharply by diabetes type. Autoimmune polyglandular syndrome type 2 links type 1 diabetes with autoimmune adrenalitis (Addison disease) and autoimmune thyroid disease. In type 1 diabetes cohorts, prevalence of adrenal autoantibodies ranges from 1.5 to 2 percent, but progression to clinical adrenal insufficiency among antibody-positive patients is high, roughly 30 to 50 percent over 10 to 15 years in follow-up studies.
In type 2 diabetes the coexistence is mostly iatrogenic, not autoimmune. Chronic exogenous glucocorticoids are the dominant cause of tertiary adrenal insufficiency, and steroid exposure is common in this population through joint injections, oral prednisone bursts, and inhaled or topical formulations. A 21-hydroxylase antibody screen is not indicated in type 2 diabetes; a medication history is.
The reason type 1 diabetes clusters with Addison disease is genetic. Both sit on the HLA-DR3-DQ2 and HLA-DR4-DQ8 haplotypes, and both are organ-specific autoimmune diseases. The shared susceptibility means a patient with one has elevated risk of the other, which is why guidelines recommend screening. Per the 2022 International Consensus on the Diagnosis and Management of Primary Adrenal Insufficiency, patients with type 1 diabetes should be offered 21-hydroxylase antibody testing at diagnosis and periodically thereafter.
Hypoglycemia frequency is the clinically loudest signal. In patients with type 1 diabetes and undiagnosed adrenal insufficiency, severe hypoglycemia episodes requiring assistance are reported at rates several times higher than matched controls before the adrenal diagnosis is made. The direction of the error is predictable: clinicians attribute the lows to tight control or insulin dose error, not to a failing adrenal gland.
Why Diabetes Treatment Masks the Diagnosis
This is the central trap. Adrenal insufficiency causes hypoglycemia, but the same patient has diabetes and is being treated with insulin or a sulfonylurea. The medication becomes the obvious suspect.
Three mechanisms hide the diagnosis. First, insulin dose reduction appears to solve the problem temporarily, so the clinician stops investigating. Second, the fatigue, weight loss, and nausea of adrenal insufficiency overlap with poor glycemic control, gastroparesis, and depression, all common in diabetes. Third, hyponatremia and hyperkalemia are read as diabetic kidney disease or medication effects rather than mineralocorticoid deficiency.
In type 1 diabetes the picture can invert. Without cortisol's counter-regulatory push, insulin sensitivity rises, so the same insulin dose produces a deeper and longer hypoglycemic effect. Patients report that their insulin-to-carb ratio changes without explanation. A ratio that suddenly needs a 20 to 30 percent reduction in a previously stable patient is a reason to check a morning cortisol.
The masking also works in the other direction. Undiagnosed adrenal insufficiency can be unmasked by an intercurrent illness or surgery, producing an adrenal crisis triggered by the stress of a diabetic emergency. Hyperglycemic crises and adrenal crises can present together, and the hypotension of one can be mistaken for dehydration from the other.
Timeline: From Onset to Diagnosis
Adrenal insufficiency develops slowly in autoimmune disease, which is why it is missed for years. The table below is a typical course for autoimmune Addison disease in a patient with type 1 diabetes. Individual timing varies widely.
| Stage | Typical timing | What the patient notices | What the labs show |
|---|---|---|---|
| Silent autoimmunity | Year 0 | Nothing | Positive 21-hydroxylase antibodies, normal cortisol |
| Subclinical insufficiency | Years 1 to 3 | Occasional unexplained lows | Rising ACTH, cortisol still in range |
| Early clinical | Years 3 to 6 | Fatigue, salt craving, more frequent hypoglycemia | Low morning cortisol, elevated ACTH, low sodium |
| Overt insufficiency | Years 5 to 10 | Weight loss, nausea, dizziness on standing | Low cortisol, high ACTH, low sodium, high potassium |
| Crisis | Any time after overt stage | Collapse during illness or surgery | Hypotension, hyponatremia, hypoglycemia, shock |
The same timeline runs faster with exogenous steroids. Tertiary adrenal insufficiency from chronic prednisone can suppress the hypothalamic-pituitary-adrenal axis in as little as three to four weeks of daily therapy at 20 mg or more. Recovery after stopping steroids takes months and is often incomplete for a year or longer.
Diagnosis: Tests, Thresholds, and the Steroid Interference Problem
Diagnosis rests on biochemistry, not symptoms. A morning (8 a.m.) serum cortisol below 3 mcg/dL with an elevated ACTH is diagnostic of primary adrenal insufficiency in most contexts. A morning cortisol above 15 mcg/dL makes the diagnosis unlikely. Values between 3 and 15 mcg/dL require a cosyntropin (ACTH) stimulation test.
The stimulation test gives 250 mcg of synthetic ACTH and measures cortisol at 0, 30, and 60 minutes. A peak cortisol below 18 mcg/dL at 30 or 60 minutes is the standard cutoff for adrenal insufficiency, though some endocrinologists use 14 to 16 mcg/dL depending on assay. Per the 2016 Endocrine Society clinical practice guideline, the 250 mcg test is adequate for most cases; the 1 mcg low-dose test is more sensitive for secondary and tertiary insufficiency.
The threshold reconciliation matters here: a morning cortisol below 3 mcg/dL is diagnostic without stimulation, a peak below 18 mcg/dL after cosyntropin is diagnostic with stimulation, and values between 15 and 18 mcg/dL are a gray zone that requires repeat testing or a low-dose test. A single number never stands alone.
The non-obvious caveat is assay interference. Patients with diabetes often take biotin for neuropathy, and biotin at doses of 5 to 10 mg daily can falsely lower or raise immunoassay cortisol results depending on platform. Patients should stop biotin 48 to 72 hours before testing. Inhaled and topical steroids can also suppress the axis enough to confound results without raising the suspicion of the clinician.
Emergency Rules: Sick-Day Management and Adrenal Crisis
Adrenal crisis is the emergency that kills, and diabetes changes how it presents. The classic picture is hypotension, hyponatremia, hyperkalemia, and hypoglycemia. In a patient with diabetes the hypoglycemia may be the first and loudest sign, and the hypotension may be attributed to dehydration from hyperglycemia.
Red flags that demand immediate action:
- Blood glucose below 70 mg/dL that does not respond to the usual 15 g of fast-acting carbohydrate within 15 minutes.
- Systolic blood pressure below 90 mmHg with dizziness on standing in a patient on insulin.
- Nausea, vomiting, and abdominal pain with salt craving in a patient with known type 1 diabetes.
- Confusion or collapse during a febrile illness in a patient taking chronic steroids.
- Hyponatremia below 130 mmol/L with hyperkalemia above 5.0 mmol/L.
Sick-day rules for adrenal insufficiency require doubling or tripling the oral glucocorticoid dose during febrile illness and using injectable hydrocortisone if vomiting prevents oral intake. In a patient with diabetes, the concurrent need to manage glucose complicates this: the stress-dose steroid raises blood glucose, so insulin requirements rise at the same time the patient is at risk of adrenal crisis. Both problems must be treated simultaneously, not sequentially.
What to Actually Do: Practical Steps for Patients With Diabetes
Positive action beats watching. The steps below are concrete and can be started at the next clinic visit.
Ask for a 21-hydroxylase antibody test if you have type 1 diabetes and any unexplained change in insulin sensitivity, especially a sudden need for less insulin. Ask for a morning cortisol and ACTH if you have unexplained hypoglycemia, salt craving, or weight loss. Carry an emergency card and a hydrocortisone injection kit if you have confirmed adrenal insufficiency. Review every steroid exposure, including joint injections and topical creams, with your clinician. Stop biotin supplements 48 to 72 hours before any cortisol blood test. Adjust insulin with your diabetes team before starting or stopping steroids, because both directions carry risk.
The insulin adjustment deserves specific numbers. When starting replacement hydrocortisone at 15 to 25 mg per day, most patients with diabetes need a 10 to 20 percent increase in basal insulin, and stress dosing during illness can require 30 to 50 percent more. When stopping chronic steroids, the reverse applies, and hypoglycemia risk rises for weeks.
Common Misconceptions and Their Corrections
Several beliefs about adrenal insufficiency and diabetes are wrong in ways that delay diagnosis.
The first misconception is that adrenal insufficiency and diabetes cannot coexist because they push glucose in opposite directions. They coexist often, and the coexistence is exactly why the diagnosis is missed. The second is that a normal random cortisol rules out the disease. Random cortisol is unreliable because secretion is pulsatile and stress-dependent; only a morning value or a stimulation test is interpretable. The third is that steroid-related adrenal insufficiency only happens with high doses. Suppression has been documented with prednisone as low as 5 mg daily taken for more than three weeks, and with potent topical and inhaled steroids.
A fourth misconception is that adrenal crisis always presents with low blood pressure. In a patient with diabetes and volume depletion from hyperglycemia, blood pressure can be normal until late, and the hypoglycemia may dominate the picture. A fifth is that once adrenal insufficiency is treated, diabetes management returns to baseline. It does not; the replacement dose restores cortisol to physiologic levels but the axis can remain blunted for months, and insulin requirements shift during that recovery.
Limitations and What Remains Uncertain
The evidence base has real gaps. Prevalence estimates for autoimmune adrenal insufficiency in type 1 diabetes come largely from European cohorts, and U.S. data are sparser. Screening intervals are not standardized; the 2022 consensus recommends periodic testing but does not specify a fixed schedule. The optimal replacement dose of hydrocortisone in patients with diabetes is debated, because standard doses of 15 to 25 mg per day can worsen glycemic control while lower doses risk under-replacement.
Assay standardization remains a problem. Cortisol immunoassays vary between platforms, and the 18 mcg/dL cutoff after cosyntropin is not equivalent across all methods. Liquid chromatography-tandem mass spectrometry is more accurate but less available. The biotin interference problem is real but under-recognized, and the number of patients affected is unknown.
Finally, the interaction between adrenal insufficiency and newer diabetes drugs is largely unstudied. SGLT2 inhibitors lower glucose by increasing urinary glucose excretion and carry a euglycemic ketoacidosis risk that could compound the metabolic stress of adrenal crisis. GLP-1 receptor agonists slow gastric emptying, which may delay oral hydrocortisone absorption during a sick day. These are plausible mechanisms, not established facts, and clinicians should treat them as cautions rather than contraindications. The safest position is vigilance: when a patient with diabetes develops unexplained hypoglycemia, changing insulin needs, or an atypical crisis, the adrenal axis belongs on the differential.